A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease.

Trial Profile

A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2013

At a glance

  • Drugs Latrepirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 04 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jun 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov (NCT00939783).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top